Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rewriting the story: can a talking therapy help people shed self-stigma and reclaim their identity?

NCT ID NCT07735481

Symptom relief Sponsor: Louise Penzenstadler Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This trial tests whether Narrative Enhancement and Cognitive Therapy (NECT), a 12-session group program, can help adults with severe mental health disorders — including substance use disorders — overcome self-stigma and promote personal recovery. About 106 participants receiving outpatient psychiatric care will be randomly assigned to either NECT plus usual care or a comparison group that does not target self-stigma. The study measures changes in recovery, self-stigma, and empowerment after the intervention and at follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Narrative Enhancement Cognitive Therapy (NECT) — a structured group intervention combining psychoeducation, cognitive restructuring, and narrative exercises
What this could lead to
If it works, NECT could offer a practical, low-cost group therapy to help people with mental health disorders reduce self-stigma and improve personal recovery.
What could go wrong
This is a relatively small trial (106 participants) testing a behavioral intervention, so results may not generalize widely. The therapy requires weekly sessions for 12 weeks, and benefits may not persist long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 106 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * DSM-5 psychiatric diagnosis within F10-F48, F60-F69, or F90, including substance use disorders * Receiving outpatient or day-hospital treatment * Diagnosed or in treatment for at least 12 months * Clinically stable for at least 3 months, with stable pharmacological treatment during this period * Clinical Global Impressions-Severity score below 6 Exclusion Criteria: * Participation in another program likely to affect social functioning or self-stigma, such as social cognitive remediation or social skills training * Acute psychiatric episode with a Clinical Global Impressions-Severity score above 6 * Medical emergency or immediate life-threatening situation at inclusion * Unable to provide informed consent * Comorbid intellectual disability * Receiving care under constraint or deprived of liberty by judicial order Insufficient ability to speak and read French

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mental disorder psychiatric disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mental disorders Substance use disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Geneva University Hospital

    Geneva, Canton of Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.